When it comes to treating lipids in patients with heart disease, the mantra may be, The lower the LDL, the better. Data from the multicenter Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial indicate that aggressive reduction of atherogenic lipoproteins prevents progression of disease.
Merck announced on September 30th that it is voluntarily withdrawing rofecoxib (Vioxx) from the worldwide market.
Physicians increasingly are aware of the need to provide prophylaxis against venous thrombosis for the medically ill patient in the hospital environment. This article attempts to separate the fact from fiction regarding VTE prophylaxis.
Breast Cancer and the Use of Statins; Warnings Issued for IBS Drugs; FDA Actions
The NIH has halted the estrogen-alone wing of the Womens Health Initiative a year before its scheduled end.
Sulfonamide Antibiotics and Sulfonamide Nonantibiotics; Autoantibodies
Before Onset of SLE; Prevention of VTE with Ximelagatran; Combined
Levothyroxine Plus Liothyronine Compared to Levothyroxine Alone in
Primary Hypothyroidism; Specific Site Involvement in Fixed Drug
Eruption; Anticoagulation Therapy for Stroke Prevention in Patients
with Atrial Fibrillation
